Please login to the form below

Not currently logged in
Email:
Password:

CytomX appoints Rachel Humphrey chief medical officer

Former VP of Eli Lilly and AstraZeneca joins the company

CytomX Therapeutics has appointed Dr Rachel Humphrey as chief medical officer.

Humphrey, who has served on the board of the directors at CytomX since March this year, was formerly VP and head of immuno-oncology at both Eli Lilly and AstraZeneca, supervising the development of numerous agents.

She said: “Since joining the CytomX board of directors in March, I have been able to see at first-hand the tremendous power of the Probody platform.

“I am excited to now be joining the management team to help build a great company that has the potential to make a real difference for patients.”

Sean McCarthy, CEO of CytomX, said: “We were thrilled to have Rachel join the board earlier this year, and having her now transition to the management team will allow us to benefit even more from her decades of experience in successful oncology product development and registration.”

Before her time at AZ and Eli Lilly, Humphrey was also VP of product development at Bristol-Myers Squibb where she led all aspects of clinical development of the skin-cancer drug Yervoy (ipilimumab).

Humphrey also spent time at Bayer where she oversaw the early and late stage clinical development of the renal cell carcinoma treatment Nexavar (sorafenib).

28th August 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...

Infographics